首款国产双靶点食欲素受体拮抗剂（DORA）失眠治疗药物，名为百眠安（通用名：法赞乐生片），已在美团药房线上首发。该创新药物适用于有入睡困难或睡眠维持困难的成年患者。美团观察到DORA类助眠药物的订单量持续实现两位数的复合增长，表明市场对新型睡眠治疗方案的需求日益增长。 AI
排序理由 一款新药品的发布。
AI 生成摘要 · Google Gemini · 来自 1 个来源。 我们如何撰写摘要 →
中国首款DORA失眠药物通过美团药房在线上线
本文如何被排名
- Signal score
- 0 / 100
- Composite score across the factors below. Higher = stronger signal that this story matters right now.
- Newsworthiness bucket
- Tool
- 一款新药品的发布。
- Source corroboration
- Single-source cluster
- Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
- Topics
- product, other
- Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
- AI-industry relevance
- Low
- Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
- Story freshness
- 72 days old
- Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.
完整方法见我们的编辑标准。
报道来源 [1]
-
我国首款失眠创新药法赞乐生上线美团药房
<p>刚刚，抗失眠创新药百乐眠®（通用名：法赞雷生片）在美团买药线上首发。这是国内首个自主研发的双重食欲素受体拮抗剂（DORA），适用于入睡或睡眠维持困难的成人患者。据悉，美团DORA类促眠药订单量保持两位数复合增长，新一代睡眠治疗方案的用户需求持续释放。</p>